Zevra Therapeutics Inc. Asset Resilience Ratio
Zevra Therapeutics Inc. asset resilience ratio. Zevra Therapeutics Inc. (ZVRA) has an Asset Resilience Ratio of 53.71% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See ZVRA defensive interval ratio to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Zevra Therapeutics Inc. (2015–2024)
Asset resilience ratio of Zevra Therapeutics Inc. from 2015 to 2024. This chart shows how Zevra Therapeutics Inc.'s Asset Resilience Ratio has changed over time. Read ZVRA total debt and obligations for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Zevra Therapeutics Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see ZVRA total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $145.07 Million | 53.71% |
| Total Liquid Assets | $145.07 Million | 53.71% |
Asset Resilience Insights
- Very High Liquidity: Zevra Therapeutics Inc. maintains exceptional liquid asset reserves at 53.71% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Zevra Therapeutics Inc. Industry Peers by Asset Resilience Ratio
Compare Zevra Therapeutics Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Zevra Therapeutics Inc. Asset Resilience Ratio by Year (2015–2024)
Zevra Therapeutics Inc. asset resilience ratio by year from 2015 to 2024. The table below shows the annual Asset Resilience Ratio data for Zevra Therapeutics Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 20.05% | $35.71 Million | $178.13 Million | +5.72pp |
| 2023-12-31 | 14.33% | $24.69 Million | $172.33 Million | -0.74pp |
| 2022-12-31 | 15.07% | $17.38 Million | $115.34 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $132.94 Million | -- |
| 2019-12-31 | 0.00% | $0.00 | $10.51 Million | -- |
| 2018-12-31 | 12.19% | $3.26 Million | $26.75 Million | -47.59pp |
| 2017-12-31 | 59.78% | $31.36 Million | $52.46 Million | -0.30pp |
| 2016-12-31 | 60.08% | $51.00 Million | $84.89 Million | +25.98pp |
| 2015-12-31 | 34.10% | $19.00 Million | $55.72 Million | -- |
About Zevra Therapeutics Inc.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under P… Read more